ACAM2000
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Smallpox Vaccine Adverse Reaction
Conditions
Smallpox Vaccine Adverse Reaction
Trial Timeline
Sep 13, 2010 → Feb 14, 2012
NCT ID
NCT01158157About ACAM2000
ACAM2000 is a phase 3 stage product being developed by Emergent BioSolutions for Smallpox Vaccine Adverse Reaction. The current trial status is completed. This product is registered under clinical trial identifier NCT01158157. Target conditions include Smallpox Vaccine Adverse Reaction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01158157 | Phase 3 | Completed |
Competing Products
20 competing products in Smallpox Vaccine Adverse Reaction